Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series

Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series

Huiying Li,1,* Tingting Yu,1,* Mingmin Huang,1 Aibin Guo,1 Xiaoping Qian,2 Zhenyu Yin1 1Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of China; 2The Comprehensive Cancer Center of Drum Tower Hospita...

Full description

Bibliographic Details
Main Authors:	Li H, Yu T, Huang M, Guo A, Qian X, Yin Z
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-09-01
Series:	OncoTargets and Therapy
Subjects:	non-small cell lung cancer leptomeningeal metastases osimertinib EGFR mutation T790M
Online Access:	https://www.dovepress.com/treatment-response-to-osimertinib-in-egfr-mutated-leptomeningeal-metas-peer-reviewed-article-OTT

Similar Items

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
by: Hardy Niu, et al.
Published: (2017-09-01)

Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer
by: Zitong ZHAO, et al.
Published: (2020-04-01)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
by: Akihiro Yoshimura, et al.
Published: (2019-03-01)

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment
by: Xin Tang, et al.
Published: (2021-09-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
by: Morichika D, et al.
Published: (2016-03-01)

Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for leptomeningeal metastasis and successful treatment with osimertinib: A case report and literature review
by: Takeo Sakurai, et al.
Published: (2021-03-01)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
by: Atsushi Osoegawa, MD, PhD, et al.
Published: (2021-07-01)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
by: Li, S., et al.
Published: (2022)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
by: Mariano Provencio, et al.
Published: (2021-03-01)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
by: Qiufan Zheng, et al.
Published: (2020-02-01)

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
by: Taira Ninomaru, et al.
Published: (2021-03-01)

Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
by: Maria Gabriela O. Fernandes, et al.
Published: (2021-05-01)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
by: Zhou R, et al.
Published: (2021-04-01)

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
by: Klempner SJ, et al.
Published: (2017-12-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
by: Saad N, et al.
Published: (2017-03-01)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
by: Cristina M. Merkhofer, MD, MHS, et al.
Published: (2021-06-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
by: Hanping Wang, et al.
Published: (2020-03-01)

Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
by: Endo, T., et al.
Published: (2022)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
by: A. A. Kolomeytseva, et al.
Published: (2020-12-01)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-08-01)

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
by: Akira Nakao, et al.
Published: (2020-06-01)

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors
by: K K Laktionov, et al.
Published: (2018-06-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
by: Mazza V, et al.
Published: (2017-07-01)

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
by: Leiming Xia, et al.
Published: (2021-07-01)

Analysis of Clinicopathological Feature and Prognosis for  Leptomeningeal Metastasis in Non-small Cell Lung Cancer
by: Min ZHU, et al.
Published: (2016-08-01)

Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon EGFR mutations: a case report and literature review
by: Hakozaki T, et al.
Published: (2019-01-01)

Findings to Leptomeningeal Metastases in Lung Cancer: A Case Report
by: Thiago Rodrigo de Noronha, et al.
Published: (2019-01-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy
by: K. A. Sarantseva, et al.
Published: (2020-12-01)

A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report
by: Sun Y, et al.
Published: (2020-11-01)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Luwei Han, et al.
Published: (2021-04-01)

Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review
by: Toshiyuki Sumi, et al.
Published: (2021-06-01)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
by: Isa Mambetsariev, et al.
Published: (2018-03-01)

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma
by: Li D, et al.
Published: (2021-07-01)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗
by: Andrew J. Piper-Vallillo, MD, et al.
Published: (2019-12-01)